{"id":3859,"date":"2000-09-16T21:46:39","date_gmt":"2000-09-16T20:46:39","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=3859"},"modified":"2014-07-01T12:06:49","modified_gmt":"2014-07-01T12:06:49","slug":"pro-542-shows-efficacy-in-trial","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/3859","title":{"rendered":"PRO-542 shows efficacy in trial"},"content":{"rendered":"<p><strong>Polly Clayden, HIV i-Base<\/strong><\/p>\n<p><strong>A report in the July issue of the Journal of Infected Diseases of a phase 1 study of PRO 542 &#8211; a recombinant antibody-like fusion protein that binds to and neutralises HIV-1 isolates, showed significant viral load reduction, good tolerability and no dose limiting toxicities, in HIV-infected adults.<\/strong><\/p>\n<p>Subjects were treated with a single intravenous infusion of PRO 542 at doses of 0.2-10 mg\/kg. The drug was well tolerated, and the AUC and peak serum concentrations increased linearly with the dose, as did reduction in HIV-1 RNA. No patient developed antibodies to PRO 542.<\/p>\n<p>Sustained antiviral effect may be achieved with dosing of PRO 542. This novel agent deserves further investigation.<\/p>\n<p>Reference:<\/p>\n<p>Single dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. Jacobson et al. J of Infect Dis 2000 Jul; 182(1):326-9<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Polly Clayden, HIV i-Base A report in the July issue of the Journal of Infected Diseases of a phase 1 study of PRO 542 &#8211; a recombinant antibody-like fusion protein that binds to and neutralises HIV-1 isolates, showed significant viral &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-3859","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/3859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=3859"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/3859\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=3859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=3859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=3859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}